CASI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CASI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CASI Pharmaceuticals has the Financial Strength Rank of 4.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate CASI Pharmaceuticals's interest coverage with the available data. CASI Pharmaceuticals's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.77. As of today, CASI Pharmaceuticals's Altman Z-Score is -11.93.
For the Biotechnology subindustry, CASI Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
CASI Pharmaceuticals's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-3.46 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $20.51 Mil.
CASI Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is
GuruFocus does not calculate CASI Pharmaceuticals's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
CASI Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
Debt to Revenue Ratio | = | Total Debt (Q: Dec. 2023 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.728 | + | 20.511) | / | 27.496 | |
= | 0.77 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
CASI Pharmaceuticals has a Z-score of -11.93, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -11.93 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (NAS:CASI) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
CASI Pharmaceuticals has the Financial Strength Rank of 4.
Thank you for viewing the detailed overview of CASI Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Wei-wu He | director, 10 percent owner, officer: Chairman and CEO | ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Weihao Xu | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Larry Zhang | officer: President | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Shrotriya Rajesh C Md | director | 157 TECHNOLOGY DRIVE, IRVINE CA 92618 |
Salisbury Franklin Cary Jr | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Yue Alexander Wu | director | C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121 |
Wealth Strategy Holding Ltd | 10 percent owner | LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK |
Alexander A Zukiwski | officer: Chief Medical Officer | 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
George Chi | officer: Chief Financial Officer | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Dapeng Li | 10 percent owner | BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008 |
Idg-accel China Growth Fund Iii L.p. | 10 percent owner | UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000 |
Spectrum Pharmaceuticals Inc | 10 percent owner | 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052 |
Sparkle Byte Ltd | 10 percent owner | P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000 |
Ken Ren | director, officer: CEO and Director | 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065 |
From GuruFocus
By PRNewswire PRNewswire • 05-17-2023
By PRNewswire PRNewswire • 04-26-2023
By PRNewswire PRNewswire • 06-03-2022
By PRNewswire • 08-11-2023
By PRNewswire • 08-01-2023
By PRNewswire PRNewswire • 03-28-2022
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 08-05-2022
By PRNewswire PRNewswire • 03-04-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.